Riskpilot← Back to searchSign inGet full accessSynMed Medicinteknik AB
ABActiveOrg 5566615893Katrinebergsvägen 6Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20047 employees
Revenue 2025
SEK 30,9M
-13% vs 2024
EBITDA margin
7.2%
-40% vs 2024
Equity ratio
50.4%
Financial strength
Net profit 2025
SEK 1,8M
-36% vs 2024
| Revenue | SEK 30,9M | -13% |
| EBITDA | SEK 2,2M | -40% |
| Net profit | SEK 1,8M | -36% |
| Total assets | SEK 12,5M | +3% |
| Equity | SEK 6,3M | -23% |
| Employees | 7 | — |
Legal name
SynMed Medicinteknik AB
Org number
5566615893
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
24 april 2004
Share capital
SEK 100 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall marknadsföra och sälja medicinteknisk utrustning inom områdena gastroenterologi, urologi och neurofysiologi samt därmed förenlig verksamhet.
Address
Katrinebergsvägen 6
Phone
+4687608300
Email
info@synmed.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 32 942 | 25 848 | 30 311 | 35 666 | 30 937 |
| Staff expenses | — | — | — | — | −6 576 |
| EBITDA | 4 089 | 840 | 2 028 | 3 732 | 2 235 |
| Depreciation & amort. | −0 | −0 | −0 | −249 | — |
| EBIT | 4 089 | 840 | 2 028 | 3 483 | 2 235 |
| Net financials | — | −9 | 41 | 15 | 4 |
| Profit before tax | 4 089 | 830 | 2 069 | 3 498 | 2 240 |
| Tax | −879 | −183 | −435 | −731 | −471 |
| Net profit | 3 210 | 647 | 1 634 | 2 767 | 1 768 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 13 069 | 10 210 | 11 785 | 12 108 | 12 527 |
| Equity | 8 444 | 6 091 | 7 075 | 8 242 | 6 311 |
| Long-term debt | 0 | 9 | 0 | 0 | — |
| Short-term debt | 4 625 | 4 109 | 4 709 | 3 866 | 6 216 |
| Total debt | 4 625 | 4 118 | 4 709 | 3 866 | 6 216 |
EBITDA margin
7.2%
This company
15.8%
Market median
-54% vs market
20212025
Equity ratio
50.4%
This company
38.2%
Market median
+32% vs market
20212025
Return on equity
28.0%
This company
18.4%
Market median
+52% vs market
20212025
Net profit margin
5.7%
This company
8.1%
Market median
-30% vs market
20212025
Asset turnover
2.47×
This company
1.12×
Market median
+121% vs market
20212025
Debt / equity
0.98×
This company
0.62×
Market median
+58% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Audit | 2022 | |
PO Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SynMed Medicinteknik AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Olof Anders Johansson Sjödin | Audit | 0 companies |
| Per Olov Gezelius | Chief Executive Officer | 0 companies |
| Per-Michael Gehlen | Chairman | 0 companies |
| Mats Uno Svensson | Deputy Board Member | 0 companies |
| Mats Inge Delin | Deputy Board Member | 0 companies |